M D Anderson Cancer Center
Houston, Texas, 77030, United States
Location status: Recruiting
Recruiting
NCT Number: NCT05046080
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix
This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.
Recruiting
Interested in participating?
Request InfoKey information
Sex eligibility
Female
Study type
Observational
Primary location
About this study
PRIMARY OBJECTIVE:
I. To perform a retrospective clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix at M D Anderson Cancer Center (MDACC) and to delineate the immunohistochemical and molecular profile of these cases.
OUTLINE:
Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients diagnosed with clear cell carcinoma of the cervix at MDACC
Treatment and study plan
Electronic Health Record Review
OtherMedical records reviewed
laboratory biomarker analysis
OtherCorrelative studies
Primary outcomes
-
Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix
Time frame: through study completion, an average of 1 year
Sponsors and collaborators
Lead sponsor
M.D. Anderson Cancer Center
Other
Registry information
Official study title
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor
Important dates
- Study start
- 2021
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Sep 16, 2021
- Registry last updated
- Feb 19, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Active, Not Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013
Acinar Cell Carcinoma, Adenocarcinoma
Birmingham, Alabama, United States
View Trial Details